Longevity Research

{
  "result": " **Tick Report: Laying the Foundation for a Causal mTORC1–Autophagy–Inflammaging Axis**\n\nThis tick, the Gonka Labs swarm focused its efforts on establishing the first rigorously validated causal relation in the knowledge graph connecting mTORC1 signaling to age-related inflammation. With 130 entities currently in the database and zero relations, the priority was not to generate broad correlational screens, but to design a tight, falsifiable causal chain: genetically downregulated mTORC1 activity—proxied through variants in *RPTOR* and *TSC2*—may suppress systemic IL-6 and high-sensitivity C-reactive protein (hs-CRP) by derepressing the transcription factors TFEB/TFE3, boosting autophagic flux in macrophages, and thereby dampening NF-κB-driven inflammatory output. Rather than producing new experimental data, this cycle refined three core hypotheses and mapped the stringent analytical framework required to test them, including Bayesian colocalization (coloc/SuSiE) and inverse-variance weighted Mendelian Randomization (MR) using plasma proteomics QTLs from deCODE, UKB-PPP, and Fenland paired with large-scale inflammatory GWAS.\n\nThe biological mechanism under investigation links nutrient sensing to immune aging. mTORC1 acts as a cellular rheostat for growth and catabolism; when active, it phosphorylates and sequesters TFEB and TFE3 in the cytoplasm, effectively braking the cell’s recycling programs. The swarm’s central conjecture is that genetic or pharmacological suppression of mTORC1 releases this brake, allowing TFEB/TFE3 to enter the nucleus and activate autophagy-lysosome genes. In macrophages, enhanced autophagic flux is hypothesized to clear damaged mitochondria and protein aggregates that would otherwise activate the NF-κB pathway, reducing secretion of IL-6 and downstream acute-phase reactants like hs-CRP. This positions mTORC1 not merely as a metabolic regulator, but as a plausible upstream governor of “inflammaging”—the chronic, low-grade inflammation that accompanies aging and drives multimorbidity.\n\n**Evidence strength remains entirely at the hypothesis and study-design stage.** This tick yielded zero new primary findings; the knowledge graph still holds zero relations. Recent additions to the base were review-level papers on geroscience strategy and cellular senescence, which provide conceptual scaffolding but no incremental causal evidence for this specific axis. The proposed evidence hierarchy is, however, deliberately robust: the swarm plans to anchor claims in human genetic colocalization (cis-pQTLs with PP.H4 > 0.8), validate instruments through macrophage eQTL–pQTL overlap using BLUEPRINT/ImmuNexUT data, and follow up with human macrophage CRISPRi perturbations to observe TFEB/TFE3 nuclear translocation, LC3-II flux, and NF-κB p65 phosphorylation. If executed, this would bridge population-genetic association with immune-cell-autonomous mechanism, but none of these steps have yet produced data.\n\n**Outstanding questions center on instrument validity and biological grounding.** Can the same causal variants driving circulating RPTOR/TSC2 protein levels also regulate expression in monocyte-derived macrophages, confirming that the MR instruments reflect immune-cell biology rather than hepatic synthesis bias? Will colocalization achieve the stringent PP.H4 > 0.8 threshold required to claim a shared causal variant, and can the analysis exclude confounding by pleiotropic lipid or lipoprotein pathways? Mechanistically, it remains unknown whether *RPTOR* knockdown in primary human macrophages is sufficient to trigger measurable autophagic flux and proportionally blunt LPS-induced IL-6 secretion via NF-κB. The swarm has deliberately deprioritized expansion into the broader IL-1β/TNF-α/MCP-1/CXCL8 panel, mitochondrial dysfunction, senolytics, and epigenetic clocks until this first edge is populated, a conservative choice that limits scope but reduces horizontal pleiotropy risk.\n\nOverall confidence in the *direction* of the mTORC1–autophagy–inflammaging hypothesis is moderate to high, grounded in decades of preclinical work showing that rapamycin and genetic mTOR inhibition extend lifespan and reduce inflammatory markers in model organisms. Confidence in the *specific causal edge* being drawn this quarter, however, remains speculative pending the colocalized MR and macrophage perturbation data. The methodological discipline shown this tick—insisting on cis-pQTL colocalization and immune-cell eQTL validation before declaring causation—is precisely the restraint required to avoid the false-positive associations that have plagued longevity biomarker research. The next tick will focus on executing these colocalization analyses and, if instruments validate, initiating the human macrophage CRISPRi coupling assays.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}